Chemical inhibitors of C6orf128 target various signaling pathways and cellular processes that are essential for the protein's function. Wortmannin and LY294002, as inhibitors of phosphoinositide 3-kinases (PI3K), disrupt PI3K-mediated signaling which is vital for a myriad of cellular functions including membrane trafficking and cell survival, processes that C6orf128 may be dependent on. Similarly, the inhibition of MEK1/2 by PD98059 and U0126, and the inhibition of p38 MAP kinase by SB203580, interfere with the MAPK/ERK signaling cascade. C6orf128 relies on this cascade for activating downstream processes that are crucial for its function. SB203580 specifically halts stress-activated pathways that could be integral to C6orf128's role in the cell. Furthermore, SP600125, by inhibiting JNK, disrupts signaling that C6orf128 may require for mediating cellular responses to external stimuli.
Moreover, Rapamycin, by inhibiting mTOR, intervenes in cell growth and metabolism control systems that C6orf128 could be a part of. This inhibition can result in a cessation of C6orf128's function if it is intertwined with mTOR's regulatory roles. Gefitinib and Erlotinib, which target EGFR tyrosine kinase, would lead to the inhibition of C6orf128 if the protein operates within the EGFR signaling pathways, which are pivotal for cell proliferation and survival. ZM-447439's role as an Aurora kinase inhibitor affects cell cycle progression, and thus, inhibits C6orf128 if its function is associated with cell cycle control mechanisms. Staurosporine, a broad-spectrum kinase inhibitor, can obstruct C6orf128's action by preventing phosphorylation, a post-translational modification that C6orf128 may require for its activity. Lastly, Bisindolylmaleimide I, as a PKC inhibitor, can halt C6orf128's activity if it is reliant on PKC-mediated signaling for executing its cellular functions. Each of these chemicals, by targeting specific cellular pathways, leads to the effective inhibition of C6orf128, demonstrating the intricate interplay between signaling pathways and protein function within the cell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
As an inhibitor of phosphoinositide 3-kinases (PI3K), Wortmannin can inhibit C6orf128 if the protein's activity relies on PI3K-mediated signaling for membrane trafficking or cell survival processes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that would inhibit C6orf128 by disrupting PI3K-dependent signaling pathways, which may be crucial for C6orf128's function in cellular processes. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 inhibits MEK1/2, which are upstream in the MAPK/ERK pathway. Inhibition of this pathway can inhibit C6orf128 by preventing activation of downstream processes that require MEK1/2 signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, similar to PD98059, and inhibits C6orf128 by blocking the MAPK/ERK signaling cascade that might be necessary for its activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
This compound inhibits p38 MAP kinase, which could be essential for the stress-activated pathways that C6orf128 is involved in, thus inhibiting its function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
As an inhibitor of JNK, SP600125 would inhibit C6orf128 by blocking the JNK signaling that may be required for C6orf128-mediated cellular responses. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
By inhibiting mTOR, Rapamycin would inhibit C6orf128 if the protein's function is connected to mTOR's role in controlling cell growth and metabolism. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits EGFR tyrosine kinase; inhibition of EGFR can lead to the inhibition of C6orf128 if the protein's function is downstream of the EGFR signaling pathway. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Similar to Gefitinib, Erlotinib inhibits EGFR and would inhibit C6orf128 if this protein operates downstream of the EGFR signaling pathways. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
As an Aurora kinase inhibitor, ZM-447439 inhibits C6orf128 by possibly affecting cell cycle progression or other functions that require Aurora kinase activity. | ||||||